Angiotensinogen gene variation associated with variation in blood pressure in aboriginal Canadians

Hypertension

Volumn 29, Issue 5, 1997, Pages 1073-1077

  Hegele, Robert A ^a   Harris, Stewart B ^b   Hanley, Anthony J G ^c   Sun, Fang ^a   Connelly, Philip W ^a   Zinman, Bernard ^c  

^a ST MICHAEL'S HOSPITAL   (Canada)

^b UNIVERSITY OF WESTERN ONTARIO   (Canada)

^c MOUNT SINAI HOSPITAL   (Canada)

Author keywords

atherosclerosis; insulin; lipoproteins; obesity

Indexed keywords

ANGIOTENSINOGEN; DNA; INSULIN; LIPOPROTEIN;

ABORIGINE; ADULT; AGED; ALLELE; ARTICLE; ATHEROSCLEROSIS; BLOOD PRESSURE MEASUREMENT; CANADA; DISEASE ASSOCIATION; FEMALE; GENETIC VARIABILITY; GENOTYPE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OBESITY; PHENOTYPE; PRIORITY JOURNAL; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM;

EID: 0030954135     PISSN: 0194911X     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.HYP.29.5.1073     Document Type: Article

References (28)

1. Ward RH. Familial aggregation and genetic epidemiology of blood pressure. In: Laragh JH, Brenner BM, eds. Hypertension: Pathophysiology, Diagnosis and Management. New York, NY: Raven Press Publishers; 1990:81-100.
2. Williams RR, Hunt SC, Hopkins PN, Hasstedt SJ, Wu LL, Lalouel JM. Finding the genes for human hypertension. In: Woodford FP, Davignon J, Sniderman A, eds. Atherosclerosis X. Amsterdam, Netherlands: Elsevier Science BV; 1994:856-861.
3. Jeunemaitre X, Soubrier F, Kotelevtsev YV, Lifton RP, Williams CS, Carru A, Hunt SC, Hopkins PN, Williams RR, Lalouel J-M, Corvol P. Molecular basis of human hypertension: role of angiotensinogen. Cell. 1992;71:169-180.
4. Bloem LJ, Manatunga AK, Tewksbury DA, Pratt JH. The serum angiotensinogen concentration and variants of the angiotensinogen gene in white and black children. J Clin Invest. 1995;95:948-953.
5. Rotimi C, Morrison L, Cooper A, Oyejide C, Effing E, Ladipo M, Osotemheninen O, Ward R. Angiotensinogen gene in human hypertension: lack of an association of the T235 allele among African Americans. Hypertension. 1994;24:591-594.
6. Hata A, Namikawa C, Sasaki M, Sato K, Nakamura T, Tamura K, Lalouel J-M. Angiotensinogen as a risk factor for essential hypertension in Japan. J Clin Invest. 1994;93:1285-1287.
7. Bennett CL, Schrader AP, Morris BJ. Cross-sectional analysis of Met235→Thr variant of angiotensinogen gene in severe familial hypertension. Biochem Biophys Res Commun. 1993;197:833-839.
8. Caulfield M, Lavender P, Farrall M, Munroe P, Lawson M, Turner P, Clark A. Linkage of the angiotensinogen gene to essential hypertension. N Engl J Med. 1994;330:1629-1633.
9. Ward K, Hata A, Jeunemaitre X, Helin C, Nelson L, Namikawa C, Farrington PF, Ogasawara M, Suzumori K, Tomada S, Berrebi S, Sasaki M, Corvol P, Lifton RP, Lalouel J-M. A molecular variant of angiotensinogen associated with preeclampsia. Nat Genet. 1993;4: 59-61.
10. Hegele RA, Brunt JH, Connelly PW. A polymorphism of the angiotensinogen gene is associated with variation in blood pressure in a genetic isolate. Circulation. 1994;90:2207-2212.
11. Hegele RA, Evans AJ, Tu L, Ip G, Brunt JH, Connelly PW. A gene-gender interaction affecting lipoproteins in a genetic isolate. Arterioscler Thromb. 1994;14:671-678.
12. Hegele RA, Brunt JH, Connelly PW. A polymorphism of the paraoxonase gene associated with variation in blood pressure in a genetic isolate. Arterioscler Thromb Vasc Biol. 1995;15:89-95.
13. Hegele RA, Brunt JH, Connelly PW. Multiple genetic determinants of variation of plasma lipoproteins in a genetic isolate. Arterioscler Thromb Vasc Biol. 1995;15:861-871.
14. Baier LJ, Sacchettini JC, Knowler WC, Eads J, Paolisso G, Tataranni PA, Mochizuki H, Bennett PH, Bogardus C, Prochazka M. An amino acid substitution in the human intestinal fatty acid binding protein is associated with increased fatty acid binding, increased fat oxidation and insulin resistance. J Clin Invest. 1995; 95:1281-1287.
15. Hixson JE, Vernier DT. Restriction isotyping of the human apolipoprotein E by gene amplification and cleavage with HhaI. J Lipid Res. 1990;31:545048.
16. Friedman E, Carson E, Larsson C, DeMarco L. A polymorphism in the coding region of the vasopressin type 2 receptor (AVPR2) gene. Hum Mol Genet. 1993;2:1746.
17. SAS Institute Inc. SAS/STAT Guide for Personal Computers, Version 6 Edition. Cary, NC: SAS Institute Inc; 1987.
18. Walden CC, Hegele RA. Apolipoprotein E in hyperlipidemia. Ann Intern Med. 1994;120:1026-1036.
19. Hegele RA, Brunt JH, Connelly PW. Genetic and biochemical factors associated with variation in blood pressure in a genetic isolate. Hypertension. 1996;27:308-312.
20. Chan L, Boerwinkle E. Structure, function, molecular genetics and epidemiology of apolipoprotein B. Semin Liver Dis. 1992;12: 311-320.
21. Fuh MMT, Shieh SM, Wu DA, Chen YDI, Reaven GM. Abnormalities of carbohydrate and lipid metabolism in patients with hypertension. Arch Intern Med. 1987;147:1035-1038.
22. Castelli WP, Garrison RJ, Wilson PWF, Abbott RD, Kalousdian S, Kannell WB. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham study. JAMA. 1986;256: 2835-2838.
23. Stamler J, Wentworth D, Neaton JD. Is the relationship between serum cholesterol and risk of premature death from coronary heart disease continuous and graded? Findings in 356 222 primary screenees of the Multiple Risk Factor Intervention Trial (MRFIT). JAMA. 1986;256:2823-2828.
24. Reaven GM. Role of insulin resistance in human disease. Diabetes. 1988;37:1595-1607.
25. Simon BC, Cunningham LD, Cohen RA. Oxidized low density lipoproteins cause contraction and inhibit endothelium-dependent relaxation in the pig coronary artery. J Clin Invest. 1990;86:75-79.
26. Treasure CB, Klein JL, Weintraub WS, Talley JD, Stillabower ME, Kosinski AS, Zhang J, Boccuzzi SJ, Cedarholm JC, Alexander RW. Beneficial effects of cholesterol-lowering therapy on the coronary endothelium in patients with coronary artery disease. N Engl J Med. 1995;332:481-487.
27. Anderson TJ, Meredith IT, Yeung AC, Frei B, Selwyn AP, Ganz P. The effect of cholesterol-lowering and antioxidant therapy on endothelium-dependent coronary vasomotion. N Engl J Med. 1995; 332:488-493.
28. Keidar S, Kaplan M, Aviram M. Angiotensin II-modified LDL is taken up by macrophages via the scavenger receptor, leading to cellular cholesterol accumulation. Arterioscler Thromb Vasc Biol. 1996;16:97-105.